1)Stewart AF:Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373-379,2005
2)Gastanaga VM, Schwartzberg LS, Jain RK, et al:Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med 5:2091-2100,2016
3)Donovan PJ, Achong N, Griffin K, et al:PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab 100:2024-2029,2015
4)竹内靖博:副甲状腺疾患と代謝性骨疾患.日内分泌・甲状腺外会誌 35:263-267,2018
5)井上大輔:高カルシウム血症と内分泌疾患.日内会誌 109:740-745,2020
6)Guise TA, Wysolmerski JJ:Cancer-Associated Hypercalcemia. N Engl J Med 386:1443-1451,2022
7)Mirrakhimov AE:Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci 7:483-493,2015
8)Taylor GP, Matsuoka M:Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24:6047-6057,2005
9)Sternlicht H, Glezerman IG:Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag 11:1779-1788,2015
10)福原傑:高カルシウム血症と腫瘍崩壊症候群.日腎会誌 59:598-605,2017
11)Burtis WJ, Brady TG, Orloff JJ, et al:Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106-1112,1990
12)Seymour JF, Gagel RF:Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82:1383-1394,1993
13)Roodman GD:Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557-1563,1997
14)Mundy GR, Edwards JR:PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol 19:672-675,2008
15)Smith JD, Wilson S, Schneider HG:Misclassification of Calcium Status Based on Albumin-Adjusted Calcium: Studies in a Tertiary Hospital Setting. Clin Chem 64:1713-1722,2018
16)Baird GS:Ionized calcium. Clin Chim Acta 412:696-701,2011
: Calculating a “Corrected Calcium” Level. J Hosp Med 16:499-501,2021
18)Law MM, Smith JD, Schneider HG, et al:Misclassification of calcium status in end-stage kidney disease using albumin-adjusted calcium levels. Nephrology (Carlton) 26:725-732,2021